開設賬戶
模擬帳戶
關於我們
即時報價及新聞
市場分析
財經日曆
每日市場分析
交易平台
下載及介紹
使用教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
繁
简
EN
客户登入
開設賬戶
模擬帳戶
繁
简
EN
客户登入
開設賬戶
模擬帳戶
關於我們
上志國際介紹
上志國際特點
即時報價及新聞
即時報價
即時新聞
市場分析
財經日曆
市場分析
交易平台
平台特點
平台教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
關於我們
交易細則
貴金屬市場
交易平台
市場分析
推廣和資訊
常見問題
聯絡我們
繁
简
EN
Japan June seasonally unadjusted current account: deficit ¥92.3 bln, versus forecast surplus ¥1,512.0 bln and prior surplus ¥3,968.3 bln.
2026-08-10
Japan June seasonally unadjusted current account: deficit ¥92.3 bln, versus forecast surplus ¥1,512.0 bln and prior surplus ¥3,968.3 bln.
返回
其他消息
2026-08-10
Taiwan's TAIEX opened Monday, Aug. 10, at 44,707.57, up 481.66 points or 1.09%.
Taiwan's TAIEX opened Monday, Aug. 10, at 44,707.57, up 481.66 points or 1.09%.
2026-08-10
Daiichi Sankyo said Aug 10 it and Innovent Biologics have signed an exclusive entrusted promotion agreement for Vifutai (quizartinib hydrochloride tablets) in mainland China. Under the deal, Daiichi Sankyo will be responsible for clinical development, manufacturing and supply, while Innovent obtains exclusive rights to promote and will lead commercialization in the China market.
Daiichi Sankyo said Aug 10 it and Innovent Biologics have signed an exclusive entrusted promotion agreement for Vifutai (quizartinib hydrochloride tablets) in mainland China. Under the deal, Daiichi Sankyo will be responsible for clinical development, manufacturing and supply, while Innovent obtains exclusive rights to promote and will lead commercialization in the China market.
Chat with us
, powered by
LiveChat